Prostatectomy and radiation therapy show no survival difference for low-risk prostate cancer, but higher-risk cases require careful treatment consideration. The ProtecT trial supports active ...

Adding supplemental external beam radiotherapy (EBRT) did not improve outcomes in higher-risk cancer patients who had brachytherapy, according to the long-term results of two trials. Specifically, ...

A pooled analysis of five prospective trials showed that stereotactic body radiotherapy (SBRT) was associated with a lower risk for biochemical failure over 10 years vs high-dose rate brachytherapy ...

The 15-year OS rate was 60% among prostate brachytherapy recipients and 55% among EBRT recipients, indicating no significant difference between the arms. In prostate cancer, prostate brachytherapy (PB ...

HDR-BT was significantly associated with increased biochemical failure risk and acute grade 2 or higher genitourinary adverse events. In men with intermediate-risk prostate cancer, stereotactic body ...

Primary Mediastinal Germ Cell Tumors: A Real-World Analysis of Clinical Characteristics, Treatment, and Survival Outcomes From Two Tertiary Cancer Centers in India Abiraterone acetate (AA) is approved ...

Rates of acute GI and GU toxicities with dose-escalated intensity modulated proton therapy (IMPT) for the treatment of node-positive prostate cancer. This is an ASCO Meeting Abstract from the 2025 ...